Dr Yan Zhang speaks to ecancer about a phase II study of low-dose radiation (LDRT) plus durvalumab and etoposide/platinum as first-line treatment in ES-SCLC.

This study presented the efficacy and safety results from the LEAD study. The primary endpoint of this trial was progression-free survival and the secondary endpoints included overall survival and safety.

The results showed that concurrent low-dose radiation and durvalumab and etoposide/platinum present promising prolonged mPFS in 1st line ES-SCLC and were well-tolerated.